Familial central retinal vein occlusion

Eye

Volumn 22, Issue 2, 2008, Pages 308-310

  Girmens, J F ^a   Scheer, S ^a   Heron E ^a   Sahel, J A ^a   Tournier Lasserve, E ^b   Paques, M ^a  

^a FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^b Clinique de Genetique Medicale   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTIHYPERTENSIVE AGENT; CYTOSINE; PROPRANOLOL; THYMINE; TRIAMCINOLONE ACETONIDE; WARFARIN;

ADULT; AGED; ARTICLE; CASE REPORT; CENTRAL RETINA VEIN OCCLUSION; CLINICAL FEATURE; DISEASE ASSOCIATION; FAMILIAL DISEASE; FAMILY STUDY; FEMALE; FRANCE; GENE CLUSTER; GENETIC PREDISPOSITION; GLAUCOMA; HEADACHE; HEART INFARCTION; HETEROZYGOSITY; HUMAN; HYPERTENSION; MALE; MEDICAL EXAMINATION; MUTATIONAL ANALYSIS; OPHTHALMOLOGY; RETINA MACULA EDEMA; RISK ASSESSMENT;

EID: 39449104207     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6702672     Document Type: Article

References (9)

1. Bhagat N, Goldberg MF, Gascon P, Bell W, Haberman J, Zarbin MA. Central retinal vein occlusion: Report of two familial cases. Eur J Ophthalmol 1999; 9: 181-195.
2. Peris-Martinez C, Dias-Llopis M, Menezo JL. Idiopathic central retinal vein occlusion in two siblings with the 20210 G → A variant. Arch Ophthalmol 2002; 120: 1752-1754.
3. Castella A, Othenin-Girard P. About three cases of familial central retinal vein occlusion associated with a familial hyperlipoproteinemia type II. Klin Monastilb Augenheheilk 1992; 200: 346-348.
4. Puska P, Lemmelä S, Kristo P, Sankila EM, Jarvela I. Penetrance and phenotype of the Thr377Met myocilin mutation in a large finnish family of juvenile-onset and adult-onset primary open angle glaucoma. Ophthalmic Genet 2005; 2: 17-23.
5. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 1996; 114: 1243-1247.
6. The Central Vein Occlusion Study group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997; 115: 486-491.
7. Sperduto RD, Hiller R, Chew E, Seigel D, Blair N, Burton TC et al. Risk factors for hemiretinal vein occlusion: Comparison with risk factors for central and branch retinal vein occlusion: The eye disease case-control study. Ophthalmology 1998; 105: 765-771.
8. The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol 1996; 114: 545-554.
9. McGimpsey SJ, Woodside JV, Bamford L, Gilchrist SE, Graydon R, McKeeman GC et al. Retinal vein occlusion, homocysteine, and methylene tetrahydrofolate reductase genotype. Invest Ophthal Vis Sci 2005; 46: 4712-4716.